Continuous Glucose Monitoring Following Hospital Discharge
不适用
进行中(已停止招募)
NCT05360056
| 适应症 | Type 2 Diabetes |
|---|
| 分期 | 不适用 |
|---|
| 申办方 | Kathleen Dungan |
|---|
| 状态 | 进行中(已停止招募) |
|---|
| 受试者人数 | 108 人 |
|---|
| 干预(药物) | DexCom G6 |
|---|
| 开始日期 | 2022年4月26日 |
|---|
| 完成日期 | 2024年8月31日 |
|---|
| 结果公布日 | 2025年12月9日 |
|---|
摘要
In this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with T2D will receive a Dexcom continuous glucose monitor (CGM) to wear post-hospital discharge. Patients will complete surveys assessing patient-reported outcomes prior to CGM use and following completion of the study. CGM data will be captured by the patient smartphone app and analyzed. Patients will receive personalized CGM targets and alerts for hyperglycemia and hypoglycemia. Customized reports/ decision support will be sent to the usual diabetes provider. The initial observational cohort study design will be followed by an extension phase of 12 weeks in which data on continuation of use and glucose control will be collected but no further reports will be communicated to providers.
Change in TIR 70-180 mg/dl
12 weeks · percentage of time spent 70-180 mg/dl
| Dexcom CGM | 8.5 ± 28 percentage of time spent 70-180 mg/dl |
|---|
| p-value | 0.03 |
| Mean Difference (Net) | 8.51 |
% Wear Time >70%
12 weeks · Participants
| Dexcom CGM | 54 Participants |
|---|
DTSQc Score
12 weeks · score on a scale
| Dexcom CGM | 8 score on a scale |
|---|
| p-value | <0.0001 |
| Wilcoxon signed rank | 9.85 |
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。